{"id":947161,"date":"2026-03-26T16:56:19","date_gmt":"2026-03-26T20:56:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/"},"modified":"2026-03-26T16:56:19","modified_gmt":"2026-03-26T20:56:19","slug":"disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/","title":{"rendered":"Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)<\/li>\n<li>The study size was expanded to 183 participants due to patient and physician demand<\/li>\n<li>Results of the APOLLO study are expected in Q4 2026<\/li>\n<\/ul>\n<p>WATERTOWN, Mass., March  26, 2026  (GLOBE NEWSWIRE) &#8212; Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the last participant has been randomized and dosed in the pivotal Phase 3 APOLLO trial of bitopertin in EPP. Originally planned as an N=150 study, the study was expanded to 183 participants due to patient and physician demand.<\/p>\n<p>\u201cWe are pleased to have completed enrollment in our APOLLO study in less than a year and we extend our gratitude to the EPP community for their continued contributions to the development of bitopertin,\u201d said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc. \u201cThe rapid enrollment of APOLLO underscores the urgent need and strong desire for a new treatment for EPP patients. We look forward to completing this study and continuing to engage with regulators to bring bitopertin to market.\u201d<\/p>\n<p>APOLLO is a double-blind, placebo-controlled Phase 3 study of bitopertin in patients ages 12 and above with EPP and X-linked protoporphyria (XLP), that includes sites in the US, Canada, Europe, and Australia. The co-primary endpoints are average monthly total time in sunlight without pain between 10:00 and 18:00 during the last month of the 6-month treatment period and percent change from baseline in whole blood metal-free PPIX after 6 months of treatment.\u00a0Additional study design details, including powering assumptions, are provided in the corporate presentation on Disc\u2019s website. Data from APOLLO is expected in Q4 2026, after which a CRL response will be submitted with an FDA decision expected by mid-2027.<\/p>\n<p>\n        <strong>About Bitopertin<\/strong>\n      <\/p>\n<p>Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1 (GlyT1) that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter expressed on developing red blood cells and is required to supply sufficient glycine for heme biosynthesis and support erythropoiesis. Disc is developing bitopertin as a potential treatment for a range of hematologic diseases including erythropoietic porphyrias, where it has potential to be the first disease-modifying therapy. Bitopertin has been studied in multiple clinical trials in patients with EPP, including the Phase 2 open-label BEACON trial, the Phase 2 double-blind, placebo-controlled AURORA trial, an open-label extension HELIOS trial, and the Phase 3 double-blind, placebo-controlled APOLLO trial.<\/p>\n<p>Bitopertin is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide. Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021.<\/p>\n<p>\n        <strong>About Disc Medicine<\/strong>\n      <\/p>\n<p>Disc Medicine (NASDAQ:IRON) is a biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j0kTN4951YeKClHKkestdiIScVKLgb6ON3_2Z8sPV3_eqc3drcD7i4Dsjn9ipoIfN2IGC4Hvn5Xl9V_mI8Ik3RsxWtMCrT99StwiPM1Cqes=\" rel=\"nofollow\" target=\"_blank\">www.discmedicine.com<\/a>.<\/p>\n<p>\n        <strong>Disc Cautionary Statement Regarding Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding: the APOLLO clinical trial, including timing for completion and the results thereof; and engagement with regulators to bring bitopertin to market, including Disc\u2019s planned response to the FDA\u2019s complete response letter, the timing of any approval decision by the FDA, and the potential for APOLLO to serve as the basis for any such approval decision. The use of words such as, but not limited to, \u201cbelieve,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cintend,\u201d \u201cfuture,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cseek,\u201d \u201canticipate,\u201d or \u201ccould\u201d or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc\u2019s current beliefs, expectations and assumptions regarding the future of Disc\u2019s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.<\/p>\n<p>Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc\u2019s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc\u2019s product candidates; Disc\u2019s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc\u2019s planned preclinical studies and clinical trials; the timing of the availability of data from Disc\u2019s clinical trials; Disc\u2019s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc\u2019s preclinical studies and clinical trials and the risk that the results of Disc\u2019s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc\u2019s filings with the Securities and Exchange Commission, including in the \u201cRisk Factors\u201d section of Disc\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.<\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Peg Rusconi <br \/>Deerfield Group <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vnbDhTSIFbAnOZ3kL2yuCbEBgE_uqDSubPzME0ZFGhIoxRXP9KiYuYpzRG5euqaaD_yqIGq6fxLHfvG9w_pVoIrq154dNp12hXB_JDDl42cHThi29U-subIF5arguPYg\" rel=\"nofollow\" target=\"_blank\">peg.rusconi@deerfieldgroup.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong><br \/>\n        <br \/>Christina Tartaglia<br \/>Precision AQ <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eVRZ7rcVQRgnh8hj0t2rYDhmIA7Us1JIh_YvCTDuGX_uKEHxaJKrVZGHdOT0Ldy2qcOALy9fA8zQEQV2qgsemvJ41iNlmIOTXQPAjeNbAR98nJV0GyV3mtHJ2cU6eSt5uiNHtv3Pap1OP2FTIFqRhA==\" rel=\"nofollow\" target=\"_blank\">christina.tartaglia@precisionaq.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTQwOSM3NTA2MTg5IzIyMjQ3NzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTVhNjgwMDYtZDc4Yi00NDNkLThiOWYtZTRkY2MzMTdiOTAzLTEyMzYzMjYtMjAyNi0wMy0yNi1lbg==\/tiny\/Disc-Medicine-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP) The study size was expanded to 183 participants due to patient and physician demand Results of the APOLLO study are expected in Q4 2026 WATERTOWN, Mass., March 26, 2026 (GLOBE NEWSWIRE) &#8212; Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the last participant has been randomized and dosed in the pivotal Phase 3 APOLLO trial of bitopertin in EPP. Originally planned as an N=150 study, the study was expanded to 183 participants due to patient and physician demand. \u201cWe are pleased &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-947161","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP) The study size was expanded to 183 participants due to patient and physician demand Results of the APOLLO study are expected in Q4 2026 WATERTOWN, Mass., March 26, 2026 (GLOBE NEWSWIRE) &#8212; Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the last participant has been randomized and dosed in the pivotal Phase 3 APOLLO trial of bitopertin in EPP. Originally planned as an N=150 study, the study was expanded to 183 participants due to patient and physician demand. \u201cWe are pleased &hellip; Continue reading &quot;Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-26T20:56:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTQwOSM3NTA2MTg5IzIyMjQ3NzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria\",\"datePublished\":\"2026-03-26T20:56:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/\"},\"wordCount\":1069,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTQwOSM3NTA2MTg5IzIyMjQ3NzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/\",\"name\":\"Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTQwOSM3NTA2MTg5IzIyMjQ3NzM=\",\"datePublished\":\"2026-03-26T20:56:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTQwOSM3NTA2MTg5IzIyMjQ3NzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3OTQwOSM3NTA2MTg5IzIyMjQ3NzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/","og_locale":"en_US","og_type":"article","og_title":"Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria - Market Newsdesk","og_description":"Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP) The study size was expanded to 183 participants due to patient and physician demand Results of the APOLLO study are expected in Q4 2026 WATERTOWN, Mass., March 26, 2026 (GLOBE NEWSWIRE) &#8212; Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that the last participant has been randomized and dosed in the pivotal Phase 3 APOLLO trial of bitopertin in EPP. Originally planned as an N=150 study, the study was expanded to 183 participants due to patient and physician demand. \u201cWe are pleased &hellip; Continue reading \"Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-26T20:56:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTQwOSM3NTA2MTg5IzIyMjQ3NzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria","datePublished":"2026-03-26T20:56:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/"},"wordCount":1069,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTQwOSM3NTA2MTg5IzIyMjQ3NzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/","name":"Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTQwOSM3NTA2MTg5IzIyMjQ3NzM=","datePublished":"2026-03-26T20:56:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTQwOSM3NTA2MTg5IzIyMjQ3NzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3OTQwOSM3NTA2MTg5IzIyMjQ3NzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/disc-medicine-announces-completion-of-enrollment-of-phase-3-apollo-trial-of-bitopertin-in-erythropoietic-protoporphyria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/947161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=947161"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/947161\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=947161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=947161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=947161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}